Skip to main content
Clinical Trials/NCT03753750
NCT03753750
Withdrawn
Not Applicable

Evaluation of Noninvasive Spinal Cord Stimulation for Neurogenic and Idiopathic Overactive Bladder

University of Southern California1 site in 1 countryMarch 24, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Overactive Bladder
Sponsor
University of Southern California
Locations
1
Primary Endpoint
Score on overactive bladder questionnaires
Status
Withdrawn
Last Updated
3 years ago

Overview

Brief Summary

Overactive bladder (OAB) affects 12-30% of the world's population. The accompanying urinary urgency, urinary frequency and incontinence can impair the ability to work, interact in social activities and can result in poor social functioning. Multiple treatment modalities are available for overactive bladder. However, each therapy has drawbacks that limit its application in certain patient populations. For example, oral medications have significant side effects and suffer from poor adherence. Botulinum toxin injection into the bladder wall is invasive, requires re-treatment on a regular basis and carries a risk of urinary retention. Current neuromodulatory techniques are invasive and require highly-specialized care. Therefore, a need exists for a non-invasive, well-tolerated and easily administered therapy for OAB. Transcutaneous spinal cord stimulation (TSCS) has been developed and tested in able bodied individuals to initiate locomotor function as well as in the SCI population for lower extremity and upper extremity function. More recently, we have tested this SCI patients to enable lower urinary tract function and decrease detrusor overactivity, resulting in improved continence.

Registry
clinicaltrials.gov
Start Date
March 24, 2020
End Date
January 1, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Evgeniy I. Kreydin

Assistant Professor of Urology

University of Southern California

Eligibility Criteria

Inclusion Criteria

  • Age between 18 and 80 years
  • Known diagnosis of overactive bladder, confirmed by:
  • presence of urinary frequency, urgency
  • frequent small-volume voids on frequency-volume chart
  • high score on ICIQ-OAB, ICIQ-OABQOL, and OAB-q questionnaires

Exclusion Criteria

  • Younger than 18 years of age
  • Older than 80 years of age
  • Presence of lower urinary tract symptoms suggestive of urinary retention or obstruction
  • Finding of an elevated post-void residual (\>100 ml) on an ultrasonographic bladder scan
  • History of spinal cord injury, spina bifida or other neurological disease affecting the spinal cord
  • Acute or current urinary tract infection
  • History of neuromodulation for overactive bladder (sacral nerve stimulation or peripheral tibial nerve stimulation)
  • Current or planned pregnancy

Outcomes

Primary Outcomes

Score on overactive bladder questionnaires

Time Frame: 4-12 weeks

Each participant will complete two validated questionnaires pertaining to overactive bladder: OAB-q and ICIQ-OAB. The OAB-q generates a total score ranging between 33 points (best) to 198 points (worst). The ICIQ-OAB generates a total score ranging between 0 points (best) to 58 points (worst). The questionnaires will be completed at the initiation and completion of the study. Change in questionnaire scores between initiation and completion of the study will be assessed. Changes in questionnaire scores will be compared between participants in the stimulation and sham arms of the study.

Number of urination and incontinence episodes over 72 hours

Time Frame: 4-12 weeks

A voiding diary records the amount of fluid intake, the number of urinations and the number of incontinence episodes over 72 hours. The number of daily urinations and incontinence episodes will be compared at the beginning and the conclusion of the study. Changes in the number of daily urinations and incontinence episodes will be compared between participants in the stimulation and sham arms of the study.

Secondary Outcomes

  • Cystometric bladder capacity, number of detrusor overactivity episodes during urodynamic studies.(4-12 weeks)

Study Sites (1)

Loading locations...

Similar Trials